Search clinical trials for: CHF 5993 DPI

Total 3765 results

Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

COPD

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (TRI-D)

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Completed

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (TRIMARAN)

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune)

Asthma

Poland
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

Brain Cancer

United States
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Umeå University
County Council of Norrbotten, Sweden

Completed

Lifestyle Intervention in Primary Health Care - the Björknäs Study

Hypertension | Obesity | Type 2 Diabetes | Dyslipidemia

Sweden
GlaxoSmithKline

Completed

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
GlaxoSmithKline

Completed

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Asthma

Canada, United States
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Major Depressive Disorder

Poland
Sanofi

Completed

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Healthy Volunteers

United States
AlgiPharma AS
AlgiPharma Australia Pty. Ltd.

Unknown

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

Bipolar Depression

Poland
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium
Yale University

Completed

Validating Imaging Biomarkers of Small Vessel Disease in Diabetic Individuals Using Advanced MRI Techniques.

Small Vessel Disease of Diabetes Mellitus

United States
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Chiesi Farmaceutici S.p.A.

Completed

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) (TRIGGER)

Asthma

Argentina, Belarus, Bulgaria, Czechia, Germany, Hungary, Italy, Lithuania, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine, United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

COPD

United Kingdom, Ireland
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers

Healthy Volunteers

Poland
University of North Carolina, Chapel Hill
University of Texas at Austin

Completed

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques (DPI)

Adult Healthy Volunteers

United States
Forest Laboratories

Withdrawn

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

Community-Acquired Bacterial Pneumonia (CABP)
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device (NEXThalerPIF)

Asthma

Italy
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT)

Coronary Artery Disease

United States, Brazil
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (PAED4)

Asthma in Children

Denmark
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT2)

Coronary Artery Disease

United States, Argentina, Belgium, Brazil, Netherlands
Charite University, Berlin, Germany

Terminated

Action of Caffeinated and Decaffeinated Espresso on Autonomic Function

Influence of Espresso on Heart Rate Variability

Germany
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI (PIF3)

COPD

Italy
Medical College of Wisconsin
University of Wisconsin, Milwaukee; Children's Hospital and Health System Foundation... and other collaborators

Completed

Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home

Patient Discharge

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Pulmonary Disease, Chronic Obstructive

Germany
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients

Pulmonary Disease, Chronic Obstructive | Asthma

Germany
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants

Pain

United Kingdom
ARYx Therapeutics

Completed

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Atrial Fibrillation

United States
Curis, Inc.

Completed

Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

Solid Tumor

United States, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
BDD Pharma Ltd
AlgiPharma AS

Completed

A Study to Investigate Lung Deposition of Radiolabelled OligoG

Cystic Fibrosis

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan
Gazi University

Completed

Gingival Recession Treatment With Concentrated Growth Factor(CGF)

Gingival Recession
Forest Laboratories

Completed

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

Infections | Pneumonia

United States, Ukraine, Argentina, Georgia
Chiesi Farmaceutici S.p.A.
SGS S.A.

Completed

Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

COPD

United Kingdom

3

Subscribe